𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Symptomatic relief from treatment-induced psychosis in Parkinson's disease: An open-label pilot study with remoxipride

✍ Scribed by Dr. Tilak Mendis; Erich Mohr; Amanda George; Ilene N. Rusk; Peggy Gray; J. David Grimes

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
320 KB
Volume
9
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Current treatment strategies for levodopa‐induced psychosis in Parkinson's disease have had limited success. Remoxipride, a selective D~2~ receptor antagonist, was administered in an open label pilot study to seven parkinsonian patients exhibiting thought disorder. Symptoms improved significantly in six patients after treatment durations of 1–6 months and cleared completely in two individuals. One patient (at age 90 the oldest in the group) could not tolerate the compound due to significant motor deterioration, and the drug had to be discontinued after 1 week. In all remaining patients, no motor complications appeared, and therapeutic effects of remoxipride continued for up to 3 months after treatment cessation and have lasted for 2 years now in one individual. Further study of this compound in the context of treatment‐induced psychosis in Parkinson's disease appears to be warranted.

📜 SIMILAR VOLUMES

Risperidone in the treatment of dopamine
Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
✍ Erich Mohr; Tilak Mendis; Kathleen Hildebrand; Peter Paul De Deyn 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

## Purpose: To evaluate the safety and efficacy of risperidone in patients with parkinson's disease (pd) who are experiencing significant dopamine-induced psychosis. ## Patients and methods: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; John L. Maldonado; William O. Tatum; Ro 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

## Abstract We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and wer

Open-label flexible-dose pilot study to
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
✍ Joseph H. Friedman; Robert M. Berman; Christopher G. Goetz; Stewart A. Factor; W 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstr